Last May EndoChoice (Alpharetta, GA) received FDA clearance for its novel Fuse endoscopy system that provides a 330° field of view compared to traditional scopes that do up to 170°. A new study just published in The Lancet has confirmed a significant advantage to having such a wide field of view when detecting adenomas during colonoscopies.
The Fuse has multiple cameras and LED lights illuminate the scene, providing an integrated view on tablet-like touchscreen panel. In the study 88 patients had adenomas detected using traditional colonoscopy, but there was a 41% miss rate of further adenomas that were detected only using the Fuse. Additionally, of the total 185 patients in the study, pre-cancerous polyps were completely missed in five of the patients using standard colonoscopy, but spotted with the Fuse.
Some of the findings from the study abstract:
By per-lesion analysis, the adenoma miss rate was significantly lower in patients in the full-spectrum endoscopy group than in those in the standard forward-viewing procedure group: five (7%) of 67 vs 20 (41%) of 49 adenomas were missed (p<0·0001). Standard forward-viewing colonoscopy missed 20 adenomas in 15 patients; of those, three (15%) were advanced adenomas. Full-spectrum endoscopy missed five adenomas in five patients in whom an adenoma had already been detected with first-pass standard forward-viewing colonoscopy; none of these missed adenomas were advanced. One patient was admitted to hospital for colitis detected at colonoscopy, whereas five minor adverse events were reported including vomiting, diarrhoea, cystitis, gastroenteritis, and bleeding.
Article in The Lancet: Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial
Company announcement: New Study Published in The Lancet Oncology Shows EndoChoice Fuse System Detects Significantly More Pre-Cancerous Polyps…
